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Abstract
Background: TRIM62 (tripartite motif containing 62) has been found to act as a tumor suppressor of several
cancers. However, its precise biological role and related mechanism remain unknown in cervical cancer (CC).
Methods: Quantitative Real-time PCR and western blot were adopted to detect the mRNA and protein expression level
of TRIM62 in both human CC cell lines and tissues. Immunohistochemistry was used to measure the TRIM62 expression
in 30 normal cervical and 189 CC tissues. Univariate and multivariate Cox regression analyses and Kaplan–Meier survival
analyses performed to investigate the association between TRIM62 expression and CC patients’ prognosis. The effect of
TRIM62 on CC growth and metastasis was studied in vitro and in vivo. Multi-pathway reporter array were utilized to
identify the potential signaling manipulated by TRIM62.
Results: TRIM62 was frequently down-regulated in both human CC cells and tissues. Low expression of TRIM62 in CC
tissues was associated with aggressive clinicopathological features of CC patients. In addition, TRIM62 was also an
independent poor prognostic factor for overall and disease-free survival of CC patients after surgery. Moreover, enforced
expression of TRIM62 in CC cells significantly inhibited their abilities of proliferation, migration and invasion in vitro.
Besides, subcutaneous xenograft tumor model and xenograft mouse metastatic model respectively displayed that
TRIM62 impeded the growth and metastasis of CC in vivo. Furthermore, mechanism study exhibited that TRIM62 could
suppress epithelial-mesenchymal transition (EMT) by inhibiting c-Jun/Slug signaling. The inhibitory role of TRIM62 in
tumor proliferation might be through regulating cell cycle related proteins CyclinD1 and P27 by targeting c-Jun.
Conclusion: TRIM62 is a potential prognostic biomarker in CC and suppresses metastasis of CC via inhibiting c-Jun/Slug
signaling-mediated EMT.
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Background
Cervical cancer (CC) is one of the most common malig-
nant tumors in women. With the increasing uptake of
Pap smear screening and HPV vaccines in recent years,
the incidence of CC has been decreased in many coun-
tries [1]. However, there are still approximately 527,600
new cases and 265,700 deaths worldwide in 2012. Espe-
cially in developing countries, CC ranks as the second
most commonly diagnosed cancer and the third leading
cause of cancer death [2]. In China, there were about
98,900 new cases and 30,500 deaths among 2015 [3]. It
has been well known that tumor recurrence and metas-
tasis has become the major obstacle to improve the
long-term survival of CC [4, 5]. The capability for me-
tastasis enables CC cells to colonize new terrain where
nutrients and space are more abundant than the primary
site [6]. Previous researchers showed that CC metastasis
is an exceedingly complex biological process, such as
several oncogenes and/or anti-oncogenes aberrant ex-
pression and epithelial-mesenchymal transition (EMT)
[7, 8]. The common pattern of metastasis of CC is direct
extension and pelvic lymph node metastasis (PLNM),
which can occur at early stage CC. In advanced CC, me-
tastases can be present out of pelvic to distant organs,
such as lungs [5]. Although persistent infection of high-
risk human papillomavirus (HPV) is confirmed to be
associated with the development of the majority of CC
[9, 10], the molecular mechanism underlying cervical
carcinogenesis and tumor progression remain unclear
and there has been no accurate biomarker for predicting
aggressiveness and prognosis of CC so far. [11]. As a
consequence, it is of great significance to determine the
exact mechanism and discover new biomarkers that are
potentially able to be used in the prevention and treat-
ment of CC.
The progression of a primary epithelial tumor to an
invasive and metastatic tumor is usually accompanied by
the activation of EMT, which is a biologic process that
enables an epithelial cell changes to a mesenchymal cell
phenotype [12, 13]. A number of studies have found
EMT could endow epithelial cell with migratory and in-
vasive capacity, and was involved in metastasis of many
cancers including CC [14, 15]. EMT is induced by a
group of transcription factors such as Snail, Slug and
Twist. These transcription factors can mediate the
formation of a positive feedback loop via activating the
expression of either their own or other EMT transcrip-
tion factors, consequently activating the cascade of EMT
[13]. The expression of EMT transcription factors can
be activated by multiple cellular pathways, for instance
MAPK/JNK signaling. Activator protein-1 (AP-1) is one
of the major downstream transcription factors of
MAPK/JNK signaling. It is a dimeric complex, which
comprise three main subfamilies: Jun (c-Jun, JunB,
JunD), Fos (c-Fos, FosB, Fra-1, Fra-2) and ATF [16]. As
a component of AP-1, c-Jun can bind to the Slug pro-
moter and increase Slug expression, consequently indu-
cing the program of EMT [13, 17].
As a member of the TRIM/RBCC (tripartite motif or
RING finger, B-box and coiled-coil) family, TRIM62
(tripartite motif containing 62) is a RING finger E3
ubiquitin ligase [18]. Also known as DEAR1 (ductal
epithelium-associated RING chromosome 1), TRIM62
has the function of regulating cell polarity and epithelial
plasticity [19]. In 2009, Chen et al discovered that
TRIM62 was a dominant regulator of acinar morpho-
genesis in the mammary gland [20]. Later in 2013, they
further elucidated the function of TRIM62, which acted
as a chromosome 1p35 tumor suppressor and negative
regulator of TGFβ-driven EMT [21]. It is reported that
TRIM62 was highly expressed in normal epithelia, but
mutations were identified in several epithelial cancers,
including breast cancer, lung cancer, and ovarian cancer
[20–23]. Moreover, studies of breast cancer, lung cancer
and acute myeloid leukemia all demonstrated TRIM62
was a tumor suppressor and its low expression was cor-
related with poor clinical prognosis [20, 23, 24]. How-
ever, the role of TRIM62 in CC has never been explored.
In this study, we explored the expression and
biological functions of TRIM62 in CC and sought to
identify the involved mechanisms for the first time. Our
results demonstrated that TRIM62 was frequently
down-regulated in both CC tissues and cell lines.
Further analysis indicated that it was an independent
predictor of both overall survival (OS) and disease-free
survival (DFS) in early-stage CC. In addition, in vitro
and in vivo investigations showed that TRIM62 signifi-
cantly inhibited proliferation, growth and metastasis of
CC. Furthermore, mechanism study found that the
inhibitory role of TRIM62 in tumor metastasis was due
to suppression of c-Jun/Slug signaling-mediated EMT.
Its inhibitory role of proliferation might through regulat-
ing cell cycle related proteins CyclinD1 and P27 by
targeting c-Jun in CC.
Methods
Patients and tissue specimens
For detecting both the messenger RNA (mRNA) and
protein expression level of TRIM62 in cervical tissue, 20
normal cervical tissue (NCT) samples and 40 early-stage
CC tissue (28 squamous cell carcinoma and 12 adeno-
carcinoma) samples were selected for quantitative real-
time PCR (qRT-PCR). From above-mentioned tissues,
eight NCT and eight CC tissues (4 squamous cell carcin-
oma samples and 4 adenocarcinoma samples) were
selected for western blot. All samples were treated with
liquid nitrogen freezing and stored at -80 °C for later
RNA or protein extraction. Moreover, six early-stage CC
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tissue samples and paired adjacent noncancerous cer-
vical tissue (ANT) samples were collected for immuno-
histochemistry. For further study, our research enrolled
a total of 426 patients diagnosed with CC who under-
went radical hysterectomy and lymphadenectomy in the
Department of Gynecology and Obstetrics, the First
Affiliated Hospital of Sun Yat-sen University from
January 2003 to December 2010. The training cohort
contained randomly selected 108 cases in 217 patients
from January 2007 to December 2010. The validation
cohort contained randomly selected 81 cases in 162 pa-
tients from January 2003 to December 2006 (Additional
file 1: Figure S1). Thirty NCT samples were adopted as
normal control. TRIM62 expression in all the above-
mentioned tissues was detected by IHC. Histopathology
was evaluated by two pathologists in the Department of
Pathology at the First Affiliated Hospital of Sun Yat-sen
University. The comparison of the clinicopathological
features between two cohorts showed no statistically
significant differences (Additional file 2: Table S1). All
research protocols strictly complied with REMARK
guidelines for reporting prognostic biomarkers in cancer
[25]. All the enrolled CC patients were in the Ia2–IIa2
stage (early-stage). All patient materials were obtained
with informed consents. This study was approved by the
Ethics Committee of the First Affiliated Hospital of Sun
Yat-sen University.
Cell lines and cell culture
In this study, eight human cervical cancer cell lines were
used, including SiHa, HeLa, CaSki, ME180, HCC94,
HeLa229, MS751 and C33A. Among the cells above:
SiHa, HeLa, CaSki, ME180 and C33A cells were kindly
gifted by the State Key Laboratory of Oncology in South
China. HCC94, HeLa229 and MS751 were obtained
from the Type Culture Collection of the Chinese
Academy of Sciences, Shanghai, China. The cell lines
SiHa, HeLa and ME180 were cultured in DMEM
medium (Gibco BRL, Rockville, MD). The cell lines
CaSki, HCC94 and HeLa229 were cultured in RPMI-
1640 medium (Gibco BRL). The cell lines C33A and
MS751 were cultured in Eagle’s minimum essential
medium (Gibco BRL). Media were supplemented with
10 % fetal bovine serum (HyClone Laboratories, Logan,
UT) and 1 % antibiotics (100 U/ml penicillin and
100 μg/ml streptomycin) in a 5 % CO2-humidified
atmosphere at 37 °C.
RNA isolation and quantitative real-time PCR
Total RNA was isolated using RNAiso plus reagent
(TAKARA, Dalian, China) according to the manufac-
turer’s protocol and total RNA of each sample was mea-
sured quantitatively by NanoDrop ND-1000. RNA was
reverse-transcribed into cDNA by using PrimeScript RT
Master Mix (TAKARA, Dalian, China). The quantitative
real-time PCR (qRT-PCR) analyses were performed on a
7500 fast Real-Time PCR system (Applied Biosystems,
USA) utilizing SYBR Premix Ex Taq (TAKARA, Dalian,
China). In the PCR cycling (40 cycles), pre-denaturation
was accomplished in 30s at 95 °C,while the parameters
for denaturation and annealing was set at 95 °C, 5 s and
60 °C, 34 s separately. The qRT-PCR primer sequences
of TRIM62 were referenced as follows [20]: forward, 5′-
TTGATCCAAGGATGTGACATG-3′ and reverse, 5′-
GTGACCACTGTGGACTGGG-3′. The qRT-PCR was
repeated at least three times. Relative fold changes of
expression in tumor tissues against normal cervical
tissue and among different cell lines were calculated
using the comparative Ct (2-△△Ct) method. Expression
data were normalized to the geometric mean with refer-
ence to the housekeeping gene β-actin.
Western blot
Total proteins of cell lines, fresh tissue and xenografts
were extracted with cold RIPA lysis buffer supplemented
with protease inhibitor. Total proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) and then transferred onto the PVDF
membrane (Roche Life Sciences, Switzerland) as previ-
ously described. The membrane were blocked with 5 %
skimmed milk and incubated with the appropriate anti-
body. The antigen-antibody complex on the membrane
was detected with Pierce ECL Western Blotting
Substrate (Thermo Scientific, Waltham, MA). The anti-
bodies are listed in the Additional file 2: Table S6.
Immunohistochemistry
IHC staining was performed in the paraffin-embedded
tissue samples cut in 4-cm sections. First deparaffinized
in xylene and rehydrated using a series of graded alco-
hols, then slides were blocked with 10 % goat serum
before incubating with a primary antibody overnight,
followed by HRP conjugated secondary antibody incuba-
tion for 30 min at room temperature. Antibody binding
was detected by DAB and reaction was stopped by
immersion of tissue sections in distilled water once
brown color appeared. Tissue sections were counter-
stained by hematoxylin, dehydrated in graded ethanols
and mounted. The antibodies were listed in the
Additional file 2: Table S6. The positive level of immu-
nohistochemical staining was scored as described [26].
For statistical analysis, the IHC scores (ranging from 0
to 6) were evaluated and the staining score of 4 was de-
fined as the cutoff. Thus, patients with different positive
level of TRIM62 expression were divided into low- and
high-staining groups. The representative images of dif-
ferent TRIM62 expression level were shown in Fig. 2a.
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Lentivirus vectors construction and transfection
To up-regulate TRIM62 expression, the PCR-amplified
human TRIM62 coding sequence was inserted into the
NotI/BamHI site of lentivirus expression vector EF-1aF/
GFP&Puro, and then transfected into SiHa and HeLa
cells. The rescue of c-Jun expression via lentivirus trans-
fection was conducted likewise. Meanwhile the empty
lentivirus vectors transfected into SiHa and HeLa cells
were used as the negative controls. All of these lentivirus
systems were purchased from GeneChem (Shanghai,
China). Stable cell lines were selected for 10 days with
0.5 mg/ml puromycin 48 h after infection.
CCK-8 assays
To test cell viability, CCK-8 assays were performed as
the following method. The stable cell lines SiHa-NC,
SiHa-TRIM62, HeLa-NC, and HeLa-TRIM62 were
counted and 2 × 103 stably infected cells were seeded
into each well of 96-well plates. Cell viability was deter-
mined by the Cell Counting Kit-8 (CCK-8, DOJINDO,
Japan) and the microplate reader (Tecan Sunrise, Tecan
Group Ltd.) at a wavelength of 450 nm.
Colony formation assays
For colony formation assays, cells were seeded at a dens-
ity of 500 cells per 35 mm culture dish (Corning Costar
Corp, Corning, NY). Then the cells were continuously
cultured for 2 weeks. Subsequently, we removed the
medium and stained the cells with crystal violet (Key-
GEN biotech, Nanjing, China). Visible colonies (>50
cells/colony) in the dishes were manually counted and
compared. All experiments were performed independ-
ently in triplicate.
Flow cytometry assays
For flow cytometry assays, 1 × 106 cells were harvested
and washed twice with cold PBS, followed by fixation
with 70 % ethanol 24 h at 4 °C. Cell cycle analysis was
performed according to the manufacturer’s protocol of a
cell cycle detection kit (Beyotime Institute of Biotechnol-
ogy, Beijin, China). The samples were analyzed using a
Gallios flow cytometer (Beckman Coulter), and the cell
cycle distribution was analyzed by FlowJo software.
Transwell assays
Cells in culture dish were preincubated with Mitomycin-
C (10 μg/ml) for 1 h at 37 °C to suppress proliferation.
For the transwell migration assay, 2 × 104 cells in 100 μl
serum-free medium were seeded into the upper chamber
of 8-μm transwell inserts (BD Biosciences, Franklin
Lakes, NJ). In the lower chamber 500 μl medium con-
taining 10 % bovine serum albumin was added. After
20 h of incubation at 37 °C, cells in the upper chamber
were removed carefully. While cells adhering to the
underside of the membrane were fixed in methanol for
15 min and then stained with 0.1 % crystal violet
(KeyGEN biotech) for 30 min. For the transwell invasion
assays, 2 × 105 cells in 100 μl serum-free medium were
put into the upper chamber, which pre-coated with 50 μl
Matrigel (BD Biosciences, Bedford, MD) diluted 1:4 with
serum-free medium. While medium containing 10 % bo-
vine serum albumin were in the lower chamber. After
24 h of incubation at 37 °C, Matrigel and cells in the
upper chamber were removed carefully, while cells ad-
hering to the underside of the membrane were fixed in
methanol for 15 min and then stained with 0.1 % crystal
violet (KeyGEN biotech) for 30 min.
The number of cells was counted in 5 randomly se-
lected visual fields under an inverted microscope
DMI4000B (Leica, Wetzlar, Germany).
Immunofluorescence
With the purpose of cytoskeleton analysis, F-actin stain-
ing using rhodamine-phalloidin was performed. Process-
ing for immunofluorescence, cells which grown on glass
coverslips were washed twice with preheated (37 °C)
PBS for 5 min each time and fixed for 10 min in 3.7 %
formaldehyde dissolved in PBS. Then cells were perme-
abilized with 0.1 % Triton in PBS for 5 min and blocked
with 1 % bovine serum albumin (BSA) in PBS for
15 min. F-actin was stained with rhodamine-phallotoxin
(Sigma, St. Louis, MO) in PBS containing 1 % BSA for
40 min at room temperature as the manufacturer’s
protocol. Wash several times with PBS to remove un-
bound rhodamine-phalloidin. Finally cells were incu-
bated with DAPI (Roche Life Sciences, Switzerland) and
then washed three times with PBS for 5 min each time.
The samples were imaged by an automatic fluorescence
microscope BX63 (Olympus, Wetzlar, Germany).
Subcutaneous xenograft tumour model and xenograft
mouse metastatic model
In order to test the ability of forming tumors in vivo,
subcutaneous xenograft tumour model, which injecting
stable cells into nude mice, was performed. Mice were
bred and maintained under SPF conditions in the
Department of Sun Yat-sen University Animal Center, as
approved by the China Care Committee Institute. The
female BALB/c nude mice (4–6weeks of age, 18–20 g)
were randomly divided into 4 groups (n = 6/group). The
stable cells (5 × 106) including SiHa-NC, SiHa-TRIM62,
HeLa-NC, and HeLa-TRIM62 cells were injected sub-
cutaneously into the lower back of the female BALB/c
nude mice. After injection xenograft tumours were
examined twice weekly. Tumors’ length and width was
measured using calipers and volumes were calculated
according to the formula: length × width2 × 0.52, as de-
scribed previously [27]. All mice were sacrificed at the
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30th day after injection. Tumors were removed from
each mouse carefully, weighed and paraffin embedded.
Serial 6.0 mm sections were cut and subjected to immu-
nohistochemical staining.
Xenograft mouse metastatic model was performed for
comparing the metastatic capability between different
stable cell lines (SiHa-NC vs SiHa-TRIM62, HeLa-NC vs
HeLa-TRIM62). The cells (2 × 106/150 μL per mouse)
were injected intravenously into the tail vein of female
BALB/c-nu mice, respectively. After 6 weeks, the mice
were sacrificed and the lungs were removed, fixed with
3.7 % formaldehyde for Hematoxylin and Eeosin (H&E)
staining. The number of mice pulmonary metastatic foci
was confirmed and recorded by specialized pathologists.
Multi-pathway reporter array
A Cignal Finder 10-Pathway Reporter Array (SABios-
ciences, QIAGEN, USA) and Dual-Luciferase® Reporter
Assay System (Promega, USA) were adopted for the
pathway analysis. Transient transfection was performed
using Lipofectamine LTX and PLUS™ Reagents (Invitro-
gen, CA, USA). Both plasmid DNAs for the respective
signaling pathways provided in the kit as well as Lipofec-
tamine LTX and PLUS™ Reagents were diluted using
Opti-MEM (Invitrogen, USA). Relative firefly luciferase
activity was calculated and normalized to the constitu-
tively expressed Renilla luciferase. The assay was per-
formed as protocols provided in the kits.
Statistical analysis
Statistical analyses were performed using the SPSS 13.0
statistical software (Chicago, IL, USA) and MedCalc stat-
istical software (Mariakerke, Belgium). The differences
between groups were analyzed by Student’s t test. The χ2
test and Fisher’s exact test were used to analyze the rela-
tionship between TRIM62 expression and the clinico-
pathological characteristics. Survival data were evaluated
using univariate and multivariate Cox regression ana-
lyses. Survival curves were plotted by the Kaplan–Meier
method and compared using the log-rank test. In all
cases, P < 0.05 was considered statistically significant.
Results
TRIM62 is frequently down-regulated in human cervical
cancer tissues and cell lines
To explore the protein and mRNA expression of
TRIM62 in CC cell lines, we performed western blot
and qRT-PCR analyses on eight human CC cell lines,
namely SiHa, HeLa, CaSki, ME180, HCC94, HeLa229,
MS751 and C33A. TRIM62 mRNA was down-regulated
by 9.4 to 39.4 fold in all CC cell lines compared to NCT
(Fig. 1a). In consistence with these data, TRIM62 protein
was also absent or markedly decreased in 62.5 % (5/8) of
the CC cell lines assessed, including those derived from
highly invasive and/or metastatic CC (HeLa, CaSki,
ME180) (Fig. 1b).
To determine whether TRIM62 was also lowly
expressed in CC tissues, firstly 20 NCT and 40 early-
stage CC tissues were selected for qRT-PCR. Meanwhile,
eight NCT and eight early-stage CC tissues (4 squamous
cell carcinoma samples and 4 adenocarcinoma samples)
were selected randomly from above-mentioned tissues
for western blot. The results showed that TRIM62 was
less expressed in early-stage CC tissues, compared with
NCT, both protein and mRNA level. (Fig. 1c and Fig. 1d).
The expressions of TRIM62 mRNA were markedly
down-regulated in both cervical squamous cell carcin-
oma (SCC) and adenocarcinoma (AC), respectively in
comparison with those in NCT (Fig. 1c). However, the
mRNA expression of TRIM62 in SCC and in AC
demonstrated no statistical difference (P > 0.05) (Fig. 1c).
Moreover, six early-stage CC tissue samples and paired
ANT samples were performed for IHC. Compared with
matched ANT, the expression of TRIM62 in all six CC
samples was markedly down-regulated (Fig. 1e).
Furthermore, to validate the results above, 189 cases
of early-stage CC were involved for IHC. These cases
were divided into a training cohort and a validation co-
hort as it was described in Materials and Methods. For
the training cohort, TRIM62 expression was remarkably
down-regulated compared with NCT (Fig. 2a). The re-
sults showed that 62.0 % (67/108) of the specimens had
low expression of TRIM62 (Fig. 2a and Table 1). In con-
sistence with the results of training cohort, 59.3 % (48/
81) of the specimens showed low expression of TRIM62
in the validation cohort. (Fig. 2a and Table 1). Taken
together, in 189 cases of the overall cohort, 115 out of
189 specimens showed low expression of TRIM62
(Additional file 2: Table S2).
All these data suggested that the aberrant down-
regulated expression of TRIM62 was a frequent event in
early-stage CC.
Low expression of TRIM62 in early-stage cervical cancer
tissue correlates with poor clinicopathologic features and
prognosis
According to the expression of TRIM62 in early-stage
CC tissues, all of the patients were divided into a low ex-
pression group (IHC score < 4) and a high expression
group (IHC score ≥ 4). Then the relationship between
the expression of TRIM62 and clinicopathologic features
in the training cohort, the validation cohort and the
overall cohort were analyzed respectively. Significant
correlations were identified between low TRIM62 expres-
sion and several poor clinicopathologic features in the
training cohort (Table 1), including tumor size (P = 0.036),
stromal invasion (P = 0.004), PLNM (P = 0.041), recur-
rence (P = 0.001) and vital status at follow-up (P = 0.002).
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There was no obvious relationship with age, FIGO stage,
pathologic types, differentiation grade, lymphovascular
space invasion (LVSI), vaginal involvement and parame-
trial infiltration (Table 1). In the validation cohort, similar
correlation results were found. TRIM62 expression was
associated with tumor size (P = 0.016), stromal inva-
sion (P = 0.031), recurrence (P = 0.001) and vital status
at follow-up (P = 0.001) (Table 1). However, TRIM62
expression in the validation cohort was also associ-
ated with FIGO stage (P = 0.007) and differentiation
grade (P = 0.046), but not with PLNM, which were
different with that of the training cohort. Except
above results, there was no obvious relationship with
age, pathologic types, LVSI, vaginal involvement and
parametrial infiltration (Table 1). To prove whether
TRIM62 is an independent risk factor, univariate and
Fig. 1 The protein and mRNA expression of TRIM62 determined by western blot, qRT-PCR and IHC assays. The expression level of TRIM62 was
normalized to β-actin. The error bars represent standard deviation values calculated from three parallel experiments. NCT, normal cervical tissue;
CC, cervical cancer; SCC, squamous cell carcinoma; AC, adenocarcinoma; NS, no statistical significance; **, P < 0.01; ***, P < 0.001. a Analysis of the
mRNA expression level of TRIM62 in eight human CC cell lines by qRT-PCR. b Western blot analyzed the protein expression level of TRIM62 in
eight human CC cell lines (left). Quantitative analysis of TRIM62 protein expression in eight human CC cell lines was displayed (right). c Utilizing qRT-
PCR assays, TRIM62 mRNA expression were detected in 20 NCT and 40 early-stage CC tissues. There were 28 SCC and 12 AC tissues. d Western blot
assay of TRIM62 protein expression were detected in 8 NCT and 8 early-stage CC tissues, including 4 SCC and 4 AC tissues (left). Quantitative analysis of
TRIM62 protein expression in NCT and CC tissues was shown (right). e IHC assays were performed for investigating TRIM62 protein expression in six
pairs of matched cervical cancer (T) samples and adjacent nontumor cervical tissue (ANT) samples. The TRIM62 expression located in the cytoplast was
strong in NCT of ANT samples, weak or negative in T samples. Original magnifications: ×200
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Fig. 2 (See legend on next page.)
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multivariate analyses were carried out. Our data showed
that, in training cohort, TRIM62 expression (P = 0.032)
and FIGO stage (P = 0.011) were independent prognostic
factors for overall survival (OS) (Table 2). TRIM62 expres-
sion (P = 0.017) and FIGO stage (P = 0.008) were inde-
pendent prognostic factors for disease-free survival (DFS)
(Table 2). Similarly, in the validation cohort, TRIM62 ex-
pression (P = 0.038) and FIGO stage (P = 0.017) were inde-
pendent prognostic factors for OS (Table 3). TRIM62
expression (P= 0.036) and FIGO stage (P = 0.013) were in-
dependent prognostic factors for DFS (Table 3). Further-
more, in the training cohort, Kaplan–Meier survival curves
and the log-rank test survival analysis (Fig. 2b) showed that
patients in the low TRIM62 expression group had shorter
OS and DFS than that in the high expression group (P=
0.002 and P = 0.001, respectively). In the validation cohort,
similar results were found that low TRIM62 expression
group had shorter OS and DFS than that in the high expres-
sion group (P = 0.001 and P = 0.001, respectively) (Fig. 2b).
Finally, merging training cohort and validation cohort
into overall cohort, the sample size was increased, and the
similar analyses were also performed. The results demon-
strated that low expression of TRIM62 was associated
with the following factors: FIGO stage (P < 0.001), tumor
size (P = 0.002), differentiation grade (P = 0.005), stromal
invasion (P < 0.001), LVSI (P = 0.035), PLNM (P = 0.009),
vaginal involvement (P = 0.044), recurrence (P < 0.001)
and vital status at follow-up (P < 0.001) (Additional file 2:
Table S2). There was no obvious relationship with age,
pathologic types and parametrial infiltration (Additional
file 2: Table S2). TRIM62 was an independent prognosis
factor (OS: P = 0.003, DFS: P = 0.002) and its low expres-
sion associated with poor survival of CC (OS: P < 0.001,
DFS: P < 0.001) was also verified in overall cohort (Fig. 2b,
Additional file 2: Table S3 and S4).
Collectively, all these data demonstrated that TRIM62
was closely correlated with poor survival and might be
used as a novel prognostic biomarker for early-stage CC.
TRIM62 inhibits proliferation, migration and invasion of
cervical cancer cells
According to the close association between low expression
of TRIM62 and the tumor size as well as stromal invasion
in early-stage CC patients (Table 1 and Additional file 2:
Table S2), we further investigated the effects of TRIM62 on
the proliferation, migration and invasion of CC cells. As
was described above, TRIM62 protein was absent or mark-
edly decreased in 62.5 % (5/8) of CC cell lines, including
squamous and glandular CC cell lines (Fig. 1b). Therefore,
we selected the most commonly used and low-expressed
cell lines SiHa and HeLa as representatives for further stud-
ies of biological functions. TRIM62 was over-expressed in
SiHa and HeLa cell lines by stable transfection of TRIM62
overexpression lentivirus, meanwhile the empty Lentivirus
vectors were used as the negative control. The expression
of TRIM62 in each cell line (SiHa-NC, SiHa-TRIM62,
HeLa-NC, and HeLa-TRIM62) was identified by qRT-PCR
and western blot (Additional file 3: Figure S2).
Firstly, CCK8 assay and colony formation assay were
performed to assess the effect of TRIM62 on cell prolif-
eration. SiHa-TRIM62 cells with higher expressed
TRIM62 showed lower proliferation rate and less num-
ber of colonies compared with the control cells (SiHa-
NC). Similarly, HeLa-TRIM62 cells also exhibited lower
proliferation rate and less number of colonies than the
control cells, HeLa-NC (Fig. 3a and b).
Secondly, we also performed cell cycle analysis to cor-
roborate the effect of TRIM62 on proliferation of CC
cells. The results showed that over-expressed TRIM62 in
SiHa and HeLa cell lines demonstrated G1 cell cycle ar-
rest, as was evidenced by the increased percentage of G1
and the reduced percentage of G2/M (Fig. 3c). These
suggested that TRIM62 overexpression could block the
cell cycle in G1 phase.
Additionally, in order to investigate the potential role of
TRIM62 in modulating the migration and invasion ability
of CC cells, we performed transwell migration and trans-
well invasion assays. Transwell migration assays revealed
that overexpressing TRIM62 reduced the rate of migration
in both SiHa-TRIM62 and HeLa-TRIM62 cells compared
to the negative control cells (SiHa-NC or HeLa-NC), re-
spectively (Fig. 3d). Similarly, as for the transwell invasion
assays, both SiHa-TRIM62 and HeLa-TRIM62 showed re-
duced rate of invasion compared to the corresponding
negative control SiHa-NC or HeLa-NC (Fig. 3d).
These data together suggested that overexpression of
TRIM62 inhibited the proliferation, migration and inva-
sion potentialities of CC cells.
(See figure on previous page.)
Fig. 2 TRIM62 was frequently down-regulated in CC and was significantly correlated with overall survival and disease-free survival. NCT, normal
cervical tissue; CC, cervical cancer; SCC, squamous cell carcinoma; AC, adenocarcinoma. a Representative IHC images of CC tissues (SCC and AC)
with different staining intensity (upper). Representative IHC images of NCT were conducted as control (lower), in which both squamous and
glandular epithelial cells were stained throughout the cytoplasm, and the red arrows indicated the squamous epithelial cells and the blue arrows
indicated the glandular epithelial cells. Original magnification: ×100, ×200 and × 400. Bar graph shows statistics for high/low expression of NCT,
SCC and AC in the training and validation cohorts. b Survival curve was calculated with Log-rank test. The results showed the overall survival and
disease-free survival of patients with high or low TRIM62 expression in the training cohort, validation cohort and overall cohort. P value was
shown in each panel respectively
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Table 1 Correlation between TRIM62 Expression and Clinicopathologic Characteristics of Early-stage CC in Training Cohort and
Validation Cohort
Clinicopathologic Variable Training Cohort Validation Cohort
Total TRIM62 expression P-value Total TRIM62 expression P-value
low High low High
Age(years)
≦42 61 40 21 0.388 44 26 18 0.973
> 42 47 27 20 37 22 15
FIGO stage
Ia2 9 2 7 0.063 11 2 9 0.007a
Ib1 56 34 22 39 22 17
Ib2 18 12 6 14 9 5
IIa1 12 8 4 7 6 1
IIa2 13 11 2 10 9 1
Tumor size(cm)
≦4 74 41 33 0.036 54 27 27 0.016
> 4 34 26 8 27 21 6
Pathologic types
Squamous cell carcinoma 68 43 25 0.738 53 30 23 0.503
Adenocarcinoma 40 24 16 28 18 10
Differentiation grade
Well 9 4 5 0.081 7 3 4 0.046a
Moderate 48 26 22 36 17 19
Poor 51 37 14 38 28 10
Stromal invasion
< 1/2 61 30 31 0.004 50 25 25 0.031
≧1/2 47 36 11 31 23 8
Lymphovascular space invasion
Yes 14 12 2 0.050 11 8 3 0.511a
No 94 55 39 70 40 30
Pelvic-lymph node metastasis
Yes 18 15 3 0.041 14 11 3 0.106
No 90 52 38 67 37 30
Vaginal involvement
Yes 4 4 0 0.295a 3 3 0 0.267a
No 104 63 41 78 45 33
Parametrial infiltration
Yes 3 3 0 0.287a 2 2 0 0.511a
No 105 64 41 79 46 33
Recurrence
Yes 24 22 2 0.001 20 18 2 0.001
No 84 45 39 61 30 31
Vital status at follow-up
Alive 86 47 39 0.002 61 30 31 0.001
Dead 22 20 2 20 18 2
Abbreviations: FIGO the International Federation of Gynecology and Obstetrics
aP-value from Fisher’s exact test; The bold number inside the table reflected P < 0.05
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:170 Page 9 of 20
TRIM62 impedes growth and metastasis of cervical cancer
in vivo
The effect of TRIM62 expression on tumor growth and
metastasis were further verified by in vivo assays. We
adopted subcutaneous xenograft tumor model and xeno-
graft mouse metastatic model in the female BALB/c
nude mice. After continuous monitoring 30 days,
subcutaneous tumors in nude mice formed from the
Table 2 Univariate and Multivariate Analysis of Factors Associated with Overall Survival and Disease-Free Survival in Training Cohort
Clinicopathologic Variable Total OS DFS
Univariate Multivariate Analysis Univariate Multivariate Analysis
P RR (95 % CI) P P RR (95 % CI) P
Age(years)
≦42 61
> 42 47 0.424 n.a. n.a. 0.454 n.a. n.a.
FIGO stage




IIa2 13 <0.001 1.697(1.128–2.555) 0.011 <0.001 1.681(1.148–2.463) 0.008
Tumor size(cm)
≦4 74 1
> 4 34 0.035 0.650(0.203–2.078) 0.467 0.068 n.a. n.a.
Pathologic types
Squamous cell carcinoma 68




Poor 51 0.209 n.a. n.a. 0.117 n.a. n.a.
Stromal invasion
< 1/2 61 1 1
≧1/2 47 0.011 1.740(0.535–5.662) 0.357 0.012 1.327(0.507–3.474) 0.565
Lymphovascular space invasion
Yes 14 1
No 94 0.115 n.a. n.a. 0.046 0.629(0.190–2.080) 0.447
Pelvic-lymph node metastasis
Yes 18 1 1
No 90 0.029 1.609 (0.646–4.011) 0.307 0.014 2.211(0.788–6.206) 0.132
Vaginal involvement
Yes 4
No 104 0.824 n.a. n.a. 0.862 n.a. n.a.
Parametrial infiltration
Yes 3
No 105 0.434 n.a. n.a. 0.505 n.a. n.a.
TRIM62
low 67 1 1
high 41 0.008 0.200(0.046–0.873) 0.032 0.005 0.168(0.039–0.728) 0.017
Abbreviations: n.a. Not application, FIGO the International Federation of Gynecology and Obstetrics; The bold number inside the table reflected P < 0.05
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TRIM62-overexpressed group, SiHa-TRIM62 and HeLa-
TRIM62, grew dramatically slower than those from their
corresponding control group, SiHa-NC and HeLa-NC
(Fig. 4a). The mean tumor weight and tumor volume of
the TRIM62-overexpressed group, SiHa-TRIM62 and
HeLa-TRIM62, were significantly smaller than their con-
trol group, SiHa-NC and HeLa-NC, respectively (Fig. 4b
and c). To further determine the metastasis function of
Table 3 Univariate and Multivariate Analysis of Factors Associated with Overall Survival and Disease-Free Survival in Validation
Cohort
Clinicopathologic Variable Total OS DFS
Univariate Multivariate Analysis Univariate Multivariate Analysis
P RR (95 % CI) P P RR (95 % CI) P
Age(years)
≦42 44
> 42 37 0.682 n.a. n.a. 0.726 n.a. n.a.
FIGO stage




IIa2 10 <0.001 1.546(1.082–2.211) 0.017 <0.001 1.575(1.102–2.250) 0.013
Tumor size(cm)
≦4 54
> 4 27 0.191 n.a. n.a. 0.210 n.a. n.a.
Pathologic types
Squamous cell carcinoma 53




Poor 38 0.105 n.a. n.a. 0.115 n.a. n.a.
Stromal invasion
< 1/2 50 1 1
≧1/2 31 0.020 1.900(0.763–4.734) 0.168 0.024 1.819(0.735–4.502) 0.196
Lymphovascular space invasion
Yes 11
No 70 0.122 n.a. n.a. 0.182 n.a. n.a.
Pelvic-lymph node metastasis
Yes 14 1 1
No 67 0.016 2.098(0.821–5.358) 0.122 0.026 1.775(0.697–4.518) 0.229
Vaginal involvement
Yes 3
No 78 0.769 n.a. n.a. 0.662 n.a. n.a.
Parametrial infiltration
Yes 2
No 79 0.218 n.a. n.a. 0.316 n.a. n.a.
TRIM62
low 48 1 1
high 33 0.006 0.209(0.048–0.917) 0.038 0.006 0.206(0.047–0.902) 0.036
Abbreviations: n.a. Not application, FIGO the International Federation of Gynecology and Obstetrics; The bold number inside the table reflected P < 0.05
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Fig. 3 (See legend on next page.)
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TRIM62 in vivo, xenograft mouse metastatic model were
developed. After 6 weeks, lungs of the mice were
removed and the tissues were made into H&E-stained
paraffin sections. Microscopically, the incidences of
pulmonary metastasis were decreased in the TRIM62-
overexpressed groups (SiHa-TRIM62 and HeLa-TRIM62),
compared to the corresponding control groups (SiHa-NC
and HeLa-NC) (Fig. 4d and e).
Collectively, these results indicated that overexpressed
TRIM62 played a role in inhibiting growth and metasta-
sis of cervical cancer in vivo.
TRIM62 suppresses epithelial-mesenchymal transition by
inhibiting c-Jun/Slug signaling in cervical cancer
As confirmed above, both in vitro and in vivo experiments
demonstrated overexpression of TRIM62 inhibits the me-
tastasis of CC. Next we continued to identify its mechan-
ism. It is reported that both in breast cancer and lung
cancer TRIM62 was as a regulator of EMT [21, 23]. We
therefore hypothesized TRIM62 was involved in the pro-
cedure of EMT in CC as well. Consequently, we firstly ex-
amined the association between TRIM62 and EMT
markers (α-Catenin and Vimentin) expression in human
cervical cancer by IHC (Fig. 5a). It discovered that TRIM62
expression was positively correlated with α-Catenin expres-
sion (r = 0.736, P = 0.001), whereas negatively correlated
with Vimentin expression (r = -0.612, P = 0.003) in ran-
domly selected cervical cancer sections (Additional file 2:
Table S5). Moreover, expression of α-Catenin and Vimen-
tin in overexpressed TRIM62 cells (SiHa-TRIM62 and
HeLa-TRIM62) and their negative control cells were all de-
tected by western blot as well. Consistent with the IHC re-
sults, expression level of α-Catenin was up-regulated in
SiHa-TRIM62 and HeLa-TRIM62 cell lines, compared
with their corresponding controls. On the contrary, ex-
pression of Vimentin was down-regulated after over-
expression of TRIM62 in SiHa and HeLa cells (Fig. 5b).
Furthermore, rhodamine-phalloidin fluorescent staining
was used to track the influence of TRIM62 on cell
morphology. SiHa-NC and HeLa-NC cells both exhib-
ited elongated morphology with many long stretched F-
actin fibers throughout the cytoplasm (mesenchymal
phenotype-like). However, SiHa-TRIM62 and HeLa-
TRIM62 cells displayed cobblestone-like appearance
with decreased F-actin fibers (epithelial phenotype-like)
(Fig. 5c). Taken together, these data demonstrated
TRIM62 could suppress EMT in CC cells.
The potential mechanism underlying the suppressive
effect of TRIM62 on EMT in CC cell lines was further
investigated. To systemically screen out the potential sig-
naling manipulated by TRIM62, a Cignal Finder Cancer
10-Pathway Reporter Array was adopted. The results in-
dicated that MAPK/JNK signaling was dramatically sup-
pressed after TRIM62 overexpression (Fig. 5d). However,
MAPK/JNK signaling have been indicated 2 faces in can-
cer because of different AP-1 components [28, 29].
Based on the inhibitory role of TRIM62 in CC progres-
sion and MAPK/JNK signaling, we focused on the
tumor-promoting role of MAPK/JNK signaling. As a
classic proto-oncogene and a component of AP-1, c-Jun
was found to be elevated in multiple cancer types, which
shows a significant association with tumor invasion and
metastasis [16, 30, 31]. Thus we speculated c-Jun was the
main regulator of MAPK/JNK signaling after TRIM62
overexpression in CC cell lines. We next performed west-
ern blot to detect c-Jun. Notably, the expression of c-Jun
was down-regulated after overexpressing TRIM62 (Fig. 5e).
So how does the change in expression of c-Jun affect
EMT? Several researches reported c-Jun could bind to the
Slug promoter, which could result in an increase in ex-
pression of Slug and induction of EMT [13, 17]. Then we
detected the expression of Slug, and found it was also at-
tenuated in TRIM62-overexpression group (Fig. 5e). To
clarify how the expression of c-Jun was inhibited by
TRIM62, we also measured JNK1, the upstream protein of
c-Jun in MAPK/JNK signaling [32, 33]. We detected its
normal and phosphorylated forms. Results demonstrated
both normal and phosphorylated forms of JNK1 were not
affected by TRIM62 (Fig. 5f). These results indicated the
inhibitory function of TRIM62 on MAPK/JNK signaling
was through suppressing the expression of c-Jun.
With all these results taken together, it is concluded
that TRIM62 could suppress EMT by inhibiting c-Jun/
Slug signaling in CC.
Rescue of c-Jun abrogates inhibition of TRIM62 on cell
migration and invasion
Having demonstrated TRIM62 could suppress EMT by
inhibiting c-Jun/Slug signaling, we wanted to further
clarify whether the inhibition effect of TRIM62 on cell
invasion and migration was through suppressing c-Jun/
(See figure on previous page.)
Fig. 3 TRIM62 inhibits cervical cancer cells proliferation, migration and invasion in vitro. The stable cell lines SiHa-TRIM62 and HeLa-TRIM62 with
up-regulated TRIM62 expression, as well as SiHa-NC and HeLa-NC (negative control) were used in the study. *, P < 0.05; **, P < 0.01. a CCK8 assays
were used to detect the effect of TRIM62 on the viability of CC cells. b The effect of TRIM62 on colony formation of CC cells. c Flow cytometry
assays were performed to analyze the effect of TRIM62 on the cell cycle of CC cells. d The transwell migration and transwell invasion assay were
performed to investigate the effect of TRIM62 on the migration and invasion abilities of CC cell lines. Original magnification: ×100. **, P < 0.01
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Slug signaling-mediated EMT. We transfected c-Jun
overexpression lentivirus into TRIM62-overexpressed
cells, and the rescue of c-Jun expression in these cells
was validated by western blot (Fig. 6a). Firstly, the ex-
pression level of α-Catenin was significantly decreased
after overexpression of c-Jun in TRIM62-overexpressed
cells. While the expression level of Vimentin was signifi-
cantly increased after overexpression of c-Jun in
TRIM62-overexpressed cells (Fig. 6b). Then cell function
assays were performed. We detected cell morphology
with rhodamine-phalloidin fluorescent staining. It dem-
onstrated that epithelial phenotype-like morphology of
TRIM62-overexpressed cells changed back to mesenchy-
mal phenotype-like morphology after rescuing the ex-
pression of c-Jun (Fig. 6c). Morever, transwell migration
and transwell invasion assays were further adopted.
Results showed the inhibited migration and invasion by
gain of TRIM62 were significantly abrogated after over-
expression of c-Jun in TRIM62-overexpressed cells
(Fig. 6d). All these results suggested rescue of c-Jun
could abrogate inhibition of TRIM62 on cell migration
and invasion.
TRIM62 regulates the expression of CyclinD1 and P27 via
targeting c-Jun in cervical cancer
We next tried to explore the mechanism of the inhibi-
tory role of TRIM62 on proliferation in CC. As detailed
above, TRIM62 overexpression could block the cell cycle
in G1 phase. Thus we detected the expression of cell
cycle related protein CyclinD1, a key regulator of the G1
to S phase transition, and P27, a negative regulator of
the cell cycle by inhibiting cell progression to S phase.
Western blot analysis revealed that CyclinD1 was down-
regulated, whereas P27 was up-regulated in TRIM62
overexpressed cells compared with the negative control
cells (Additional file 4: Figure S3A). It implied that
TRIM62 overexpression resulted in lower expression of
CyclinD1 with higher expression of P27. The results sug-
gested that the inhibitory role of TRIM62 in CC prolifera-
tion might through decreasing the expression of CyclinD1
and increasing the P27 expression, which could lead to
blocking the cell cycle in G1 phase. But how could
TRIM62 alter the expression of CyclinD1 and P27? As
confirmed above, TRIM62 could suppress MAPK/JNK
signaling by down-regulating c-Jun. In addition, MAPK/
JNK signaling also has been reported to participate in cell
proliferation and tumor growth, and CyclinD1 and P27
could be regulated by c-Jun [34, 35]. So we hypothesized
that these changes caused by TRIM62 were through
targeting c-Jun. We detected the expression level of
CyclinD1 and P27 before and after c-Jun overexpressed in
TRIM62-overexpressed cells by western blot. Results dis-
played the expression level of CyclinD1 was significantly
increased after overexpression of c-Jun. While the expres-
sion level of P27 was significantly decreased after c-Jun
overexpression (Additional file 4: Figure S3B). All these re-
sults suggested TRIM62 regulated the expression of cell
cycle regulator CyclinD1 and P27 via targeting c-Jun. This
might be the potential molecular mechanism that leads to
reduced cell proliferation after TRIM62 overexpression.
Discussion
To date, approximately 100 human TRIM genes have
been identified and their alterations are associated with
diverse pathological conditions, such as developmental
disorders, neurodegenerative diseases, viral infections
and cancer [36, 37]. Previous evidence indicates that
whether TRIMs function as oncogenes or tumor
suppressor genes is context dependent. For example,
TRIM25 is overexpressed in ovarian cancer, but is
down-regulated in endometrial cancer [36]. Here we ex-
plored the role of TRIM62 in CC and identified that
TRIM62 was not only frequently down-regulated in both
CC tissues and cell lines, but also acted as an independ-
ent predictor of both OS and DFS in early-stage CC.
Moreover, it significantly inhibited proliferation and me-
tastasis of cervical cancer both in vitro and in vivo,
which suggested that TRIM62 played as a tumor sup-
pressor in CC. In addition, mechanism research indi-
cated TRIM62 could suppress tumor metastasis via
inhibiting c-Jun/Slug signaling-mediated EMT, and its
inhibitory role in tumor proliferation might be through
regulating cell cycle related proteins CyclinD1 and
P27 by targeting c-Jun in CC. To the best of our
knowledge, this is the first study exploring the rela-
tionship between TRIM62 and CC progression. How-
ever, there still exist several potential problems to be
further discussed and explored.
(See figure on previous page.)
Fig. 4 TRIM62 impedes growth and metastasis of cervical cancer in vivo. Effect of TRIM62 on tumor growth and metastasis were investigated in
nude mouse xenograft model, which was built by injecting stable CC cells (SiHa-NC, SiHa-TRIM62, HeLa-NC and HeLa-TRIM62). **, P < 0.01; ***, P
< 0.001. a A representative picture of tumors originated from nude mice, which had subcutaneously inoculated with stable CC cells as described
above for 30 days. b Diagrams showed the calculation of the tumor weight of TRIM62 overexpressed groups (SiHa-TRIM62 and HeLa-TRIM62)
compared with that of the corresponding control groups (SiHa-NC and HeLa-NC) (n = 6). c Subcutaneous tumor growth curves of each group were
displayed (n = 6). d Typical H&E images of pulmonary metastatic foci in control groups and normal pulmonary tissues in TRIM62 overexpressed groups
were shown, which indicating the metastatic capacity was decreased on TRIM62 overexpressed groups. Original magnification: ×100, ×200 and × 400.
e The diagrams showed the percentages of mice with or without metastatic foci in the lungs (n = 6)
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First of all, as for the correlation analyses between
TRIM62 expression and clinicopathologic characteris-
tics, we noticed several different results between the
training cohort and the validation cohort. PLNM was
one of the different results, which was considered as a
critical factor for determining the individualized treat-
ment and prognosis of cervical cancer, particularly in
early-stage CC [38]. Limited by the sample size of valid-
ation cohort and the lack of multicenter statistics, we
cannot deny the correlation of TRIM62 with PLNM. In
addition, it has been well documented that the most
common pattern of metastasis of CC is direct extension.
This study showed that TRIM62 low-expression was sig-
nificantly associated with stromal invasion, which was an
indicator of direct extension. As a result, we supposed
down-regulation of TRIM62 might take part in the me-
tastasis of early-stage CC mainly through accelerating
direct extension. Moreover, this result also supported
the functional research that demonstrated the inhibition
effect of TRIM62 on tumor metastasis.
In mechanism studies, we principally focused on clari-
fying how TRIM62 suppressed CC metastasis, as local
invasion and distant metastasis rather than cell prolifera-
tion itself are the cause of 90 % of human cancer deaths
[6, 14, 39]. Previous studies indicated TRIM62 was a
suppressor of EMT in breast cancer and lung cancer
[21, 23]. In this study we obtained the similar results
that TRIM62 could inhibit EMT in CC. However, differ-
ent from the results found in breast cancer that TRIM62
acted as a master regulator on EMT by blocking TGF-β
signaling [21], the results of Multi-pathway reporter
array showed that in CC TGF-β signaling was not
significantly affected by TRIM62. We identified that
TRIM62 could suppress MAPK/JNK signaling by down-
regulating c-Jun and inhibit EMT via targeting c-Jun/
Slug signaling in CC. Additionally, we for the first time
explored the relationship between TRIM62 and cell pro-
liferation, and found that TRIM62 overexpression could
block the cell cycle in G1 phase. As TRIM62 could sup-
press MAPK/JNK signaling by down-regulating c-Jun
and accumulating evidences demonstrated MAPK/JNK
signaling also participated in cell proliferation and tumor
growth, we next tried to clarify the possible link between
MAPK/JNK signaling and TRIM62 in the aspect of CC
proliferation. Our results suggested that TRIM62 regu-
lated the expression of cell cycle regulator CyclinD1 and
P27 via targeting c-Jun in CC, which might be the mo-
lecular mechanism of TRIM62 inhibiting proliferation in
CC. We observed that overexpressed c-Jun in TRIM62
overexpression CC cells resulted in up-regulated CyclinD1
expression and down-regulated P27 expression. It is
reported that c-Jun was able to activate the promoter of
cyclinD1 [34], and CyclinD1 could act as a negative
regulator of P27 [40]. So we speculated c-Jun might up-
regulate CyclinD1 expression by activating its promoter,
consequently down-regulating P27 expression. However,
Khattar et al also indicated that c-Jun could combine with
c-Fos forming one kind of AP-1 complexes (c-Jun/c-Fos)
thereby resulting in P27 down-regualtion [35]. Thus the
underlying mechanism of down-regulated P27 by c-Jun
needs further investigation. Furthermore, our results sug-
gested that the function of TRIM62 suppressing both CC
proliferation and metastasis was through down-regulating
c-Jun expression. But how did TRIM62 attenuate the ex-
pression of c-Jun? Multiple E3 ligases such as COP1,
ITCH and FBW7 have been reported to mediate the ubi-
quitination and proteasomal degradation of c-Jun [41–43].
Identification of additional ubiquitin ligases that regulate
the ubiquitination of c-Jun will provide a better under-
standing of the regulation of c-Jun. As a RING finger E3
ubiquitin ligase [18, 19], TRIM62 has been associated with
the formation and architecture of large protein complexes.
Recent studies also showed that TRIM62 can directly bind
to SMAD3 or CARD9 thereby promoting the ubiquitina-
tion and proteasome-mediated degradation of those two
proteins [21, 44]. Therefore, we supposed that TRIM62
might bind to c-Jun and down-regulate the expression of
c-Jun by facilitating the ubiquitination and proteasomal
degradation of c-Jun. This remains to be further explored.
Our results demonstrated that the expression of
TRIM62 were markedly down-regulated at both mRNA
and protein level. So it seems that down-regulated ex-
pression of TRIM62 might undergo reduced gene tran-
scription in CC. Genomic aberrations and epigenetic
regulation are two main methods, which could down-
regulate the expression of potential tumor suppressor
genes in tumor tissues [45, 46]. Lott et al discovered that
TRIM62 gene is mutated and deleted in breast cancer.
(See figure on previous page.)
Fig. 5 TRIM62 suppresses EMT by inhibiting c-Jun/Slug signaling in cervical cancer. a Representative IHC images of TRIM62 and EMT markers (α-Ca-
tenin and Vimentin). Original magnification: ×400. b Western blot analysis of α-Catenin and Vimentin expression in CC cells with or without TRIM62
overexpression. Beta-actin was used as a loading control. c Representative immunofluorescence images showed that TRIM62 affects the cellular
morphology of CC cells. Cell nuclei were stained with DAPI (blue) and cytoskeleton (F-actin) were stained with rhodamine-phalloidin (red). Compared
with the control cells respectively, SiHa-TRIM62 and HeLa-TRIM62 cells which overexpressed TRIM62 displayed cobblestone-like appearance with
decreased F-actin fibers. Original magnification: ×400. d 10-Pathway Reporter Array showed the signaling changes in TRIM62-overexpressed cells
compared with their corresponding controls. **, P < 0.01. e Protein expression levels of c-Jun and Slug detected by western blot were shown in
indicated cells. f Protein levels of normal and phosphorylated form of JNK1 detected by western blot were shown in indicated cells
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However, they analysis both 14 breast cancer cell lines
and 20 tumor samples and did not found promoter
methylation existing in any of the samples [20]. Thus we
speculated that down-regulated TRIM62 in CC might
probably be caused by the mutation and deletion of
TRIM62 gene. This needs to be further investigated.
Conclusions
In conclusion, our data suggest that TRIM62 could serve
as a novel prognostic indicator for early-stage CC pa-
tients. In addition, in vitro and in vivo experiments vali-
dated the inhibitory role of TRIM62 in CC growth and
metastasis. Meanwhile, we further found the inhibitory
role of TRIM62 in metastasis was through suppressing
c-Jun/Slug signaling-mediated EMT. The inhibitory role
of TRIM62 on tumor proliferation might be through
regulating cell cycle related proteins CyclinD1 and P27
by targeting c-Jun in CC. Therefore, we suppose strat-
egies designed to up-regulate TRIM62 may provide a
promising method to alleviate CC progression.
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Additional file 1: Figure S1. Flow diagram of CC patients enrolled in
this study. (TIF 196 kb)
Additional file 2: Supplementary tables of this study. (DOCX 39 kb)
Additional file 3: Figure S2. Transfection related results. The expression
level of TRIM62 was normalized to β-actin. The error bars represent standard
deviation values calculated from three parallel experiments. *, P< 0.05; **, P<
0.01. (A) Representative light-field and fluorescence images of stable CC cells
(SiHa-NC, SiHa-TRIM62, HeLa-NC and HeLa-TRIM62). The green fluorescence
protein was detected in an inverted fluorescence microscope DMI4000B
(Leica, Wetzlar, Germany). Original magnification: ×100. (B) Expression of
TRIM62 protein in SiHa-Blank, HeLa-Blank and stable NC-or TRIM62-
transduced SiHa and HeLa cells. (C) Relative mRNA expression of TRIM62 in
SiHa-Blank, HeLa-Blank and stable NC-or TRIM62-transduced SiHa and HeLa
cells was detected by qRT-PCR. The expression of TRIM62 in CC cells with
TRIM62 over-expressed (SiHa-TRIM62 and HeLa-TRIM62) were dramatically
increased than that in their corresponding negative control cells (SiHa-NC
and HeLa-NC), at both mRNA and protein levels. Simultaneously, the
expression of TRIM62 between SiHa-Blank and SiHa-NC or between HeLa-
Blank and HeLa-NC showed no statistical significance. (TIF 1059 kb)
Additional file 4: Figure S3. The expression level of cell cycle related
proteins CyclinD1 and P27. Beta-actin was used as a loading control. (A)
Western blot detected the expression level of CyclinD1 and P27 in CC
cells with or without TRIM62 overexpression. (B) Expression level of
CyclinD1 and P27 in SiHa-NC, SiHa-TRIM62, SiHa-TRIM62 + c-Jun, HeLa-NC,
HeLa-TRIM62 and HeLa-TRIM62 + c-Jun cells were detected by western
blot. (TIF 372 kb)
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Fig. 6 Rescue of c-Jun abrogates inhibition of TRIM62 on cell migration and invasion. a Expression of c-Jun protein in SiHa-NC, SiHa-TRIM62, SiHa-
TRIM62 + c-Jun, HeLa-NC, HeLa-TRIM62 and HeLa-TRIM62 + c-Jun cells was detected by western blot. b Western blot detected the expression level of α-
Catenin and Vimentin in TRIM62-overexpressed cells after overexpression of c-Jun. c Representative immunofluorescence images showed that epithelial
phenotype-like morphology of TRIM62-overexpressed cells changed back to mesenchymal phenotype-like morphology after rescuing the expression of
c-Jun. Cell nuclei were stained with DAPI (blue) and cytoskeleton (F-actin) were stained with rhodamine-phalloidin (red). Original magnification: ×400.
d The transwell migration and transwell invasion assays were performed to investigate the effect of c-Jun overexpression on the migration and invasion
abilities of TRIM62-overexpressed CC cell lines. The inhibited migration and invasion by gain of TRIM62 were significantly abrogated after overexpression
of c-Jun in TRIM62-overexpressed cells. Original magnification: ×100. *, P < 0.05; **, P < 0.01
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